Nicotinic acid mononucleotide

Overview

Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD + biosynthesis intermediate, with an IC 50 value of 93.3 μM against SARM1 . Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD + levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD + levels. Nicotinic acid mononucleotide is applicable to research related to cancer , multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Huntington's Disease | Products > Disease Areas > Multiple Sclerosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Endogenous Metabolite | Products > Signaling Pathways > Sirtuin

Product Information

• Catalog No.: HY-128700
• CAS No.: 321-02-8
• Molecular Formula: C11H14NO9P
• Molecular Weight: 335.20
• Purity: 98.08%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source